title: Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
authors.forename: Stefan
authors.initials: S
authors.lastname: Peinert
authors.forename: Dennis
authors.initials: D
authors.lastname: Carney
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: E Henry
authors.initials: EH
authors.lastname: Januszewicz
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000139:chemically induced; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001855:Bone Marrow Diseases / Q000139:chemically induced; D019070:Cell Lineage / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008875:Middle Aged; D000069283:Rituximab; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine